ABOUT GlobeImmune
NEWSROOM
CAREERS
CONTACT US
INVESTORS
Platform
Product Pipeline
Tarmogen Platform
Cancer
Oncology Pipeline
GI-4000 / Mutated Ras
GI-6207 / CEA
GI-6301 / Brachyury
Infectious Disease
Infectious Disease Pipeline
GS-4774 / HBV
GlobeImmune
|
SEC Filings
|
3/A – 2014-07-17
3/A – 2014-07-17
Print
January 1, 1970
Initial statement of beneficial ownership of securities